Golexanolone reduces peripheral inflammation and neuroinflammation and improves cognitive and motor function in hyperammonemia rats by reducing GABAA receptor activation, which is related to the reversal of the hyperammonemia‐enhanced activation in cerebellum of the TNFR1‐glutaminase‐GAT3 and TNFR1‐CCL2‐TrkB‐KCC2 pathways [102]. The gene discussed is TNFRSF1A; the disease is Hyperammonemia.